Adaptive Biotechnologies (ADPT) Net Income towards Common Stockholders (2018 - 2026)

Adaptive Biotechnologies has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$20.0 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$20.0 million, up 32.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$49.6 million (up 65.01% YoY), and the FY2025 annual result was -$59.5 million, up 62.75% from the prior year.
• Net Income towards Common Stockholders came in at -$20.0 million for Q1 2026 at Adaptive Biotechnologies, down from -$13.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $9.5 million in Q3 2025 to a low of -$69.5 million in Q4 2023.
• The 5-year median for Net Income towards Common Stockholders is -$45.3 million (2022), against an average of -$39.1 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 72.94% in 2023 and jumped 129.74% in 2025, its largest moves.
• Adaptive Biotechnologies' Net Income towards Common Stockholders stood at -$40.2 million in 2022, then slumped by 72.94% to -$69.5 million in 2023, then soared by 51.46% to -$33.7 million in 2024, then surged by 59.73% to -$13.6 million in 2025, then plunged by 47.4% to -$20.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$20.0 million (Q1 2026), -$13.6 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.